Zogenix, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZGNX research report →
Range $26 – $26
Price Chart
About the company
Zogenix, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for rare diseases within the United States, striving to profoundly improve the quality of life for affected patients and their families. Their flagship product candidate, Fintepla, a low-dose fenfluramine, is currently undergoing Phase III clinical evaluation for the management of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome.
- CEO
- Stephen Farr
- IPO
- 2010
- Employees
- 327
- HQ
- Emeryville, CA, US
Get TickerSpark's AI analysis on ZGNX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $0
- P/E
- -6.29
- PEG
- 0.85
- P/S
- 0.00
- P/B
- 8.00
- EV/EBITDA
- -0.33
- Div Yield
- 0.00%
- Gross Margin
- 94.08%
- Op Margin
- -259.56%
- Net Margin
- -278.39%
- ROE
- -82.90%
- ROIC
- -56.92%
Latest fiscal year · YoY change
- Revenue
- $81.69M+498.8%
- Gross Profit
- $76.86M+486.6%
- Op Income
- $-212,032,000
- Net Income
- $-227,413,000-8.6%
- EPS
- $-4.24-8.7%
- OCF Growth
- -10.6%
- FCF Growth
- -3.6%
- 52W High
- $26.90
- 52W Low
- $11.03
- 50D MA
- $23.18
- 200D MA
- $17.40
- Beta
- 0.90
- RSI (14)
- 78
- Avg Volume
- 3.10M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Zogenix posted another strong FINTEPLA quarter, with 20% sequential sales growth, advancing LGS and CDD expansion plans, and pushing MT 1621 toward a 2022 NDA.· November 4, 2021
- FINTEPLA global net product sales were $21.4 million, up 20% sequentially, with $18.4 million in the U.S. and $3 million in Europe.
- Total revenue was $22.6 million, up 20% from $18.8 million in the prior-year comparable period; prior-year total revenue was $2.9 million.
- The company submitted the LGS sNDA on September 27 and said the pivotal LGS study met its primary and key secondary endpoints.
- Management said U.S. momentum remains solid, with over 990 patients prescribed/referred to REMS, over 860 cumulative starts, and over 720 REMS-certified prescribers at quarter-end.
- MT 1621 timelines slipped: Study 107 moved to Q1 2022, with NDA submission now expected in the second half of 2022.
In the third quarter of 2021, Zogenix reported FINTEPLA net product sales of $21.4 million globally, up 20% sequentially from Q2 2021, including $18.4 million in the U.S. and $3 million in Europe. Total revenue was $22.6 million, up 20% versus $18.8 million in the comparable prior-year period; the company said prior-year total revenue was $2.9 million. R&D expense was $33.3 million, down from $34.4 million a year ago, while SG&A was $39.5 million versus $24.6 million a year ago. Net loss was $58 million, or $1.04 per share, versus a net loss of $60 million, or $1.08 per share, in the third quarter of 2020. The company ended the quarter with $343 million in cash and cash equivalents and marketable securities. For guidance, management said it is preparing for a potential FINTEPLA launch in LGS in 2022, expects to submit the Japan J-NDA by the end of 2021, and now expects MT 1621 NDA submission in the second half of 2022 after Study 107 moved into Q1 2022.
Stephen Farr framed the quarter as another step in a multi-indication growth story for FINTEPLA, emphasizing strong U.S. and Europe launch momentum, the LGS filing, and the nearing start of the CDD Phase 3 study. His tone was constructive and upbeat, with repeated references to expanding the commercial team, broader physician engagement, and upcoming investor events around MT 1621. He also stressed that the company is building for “short, medium and long-term” growth rather than relying on the Dravet launch alone.
Michael Smith highlighted the financial performance with $21.4 million in global FINTEPLA sales and $22.6 million in total revenue for Q3. He noted R&D of $33.3 million, including a one-time $7 million charge tied to the Nippon Shinyaku revenue-sharing amendment, and SG&A of $39.5 million due mainly to U.S. and Europe launch investment. He also pointed to a strong balance sheet with $343 million in cash and marketable securities, and reported net loss of $58 million, or $1.04 per share.
Analysts focused on patient adds, payer readiness for LGS, REMS prescriber growth, and the timing slip for MT 1621. Management said Q3 patient adds were steady despite a July-August COVID dip, that payer conversations around LGS have been encouraging, and that all patients who receive prescriptions generally obtain positive coverage decisions within two to four weeks. On MT 1621, Brad Galer said the delay was driven by pandemic-related timing on Study 107 rather than a new FDA issue, while Farr and Ashish Sagrolikar said the company is shifting emphasis toward getting more physicians engaged and certified as they see new prescribing broadening beyond epileptologists into community neurologists.
The call showed continued FINTEPLA commercial traction, with steady U.S. new starts, strong payer coverage, and growing physician awareness. Management also pointed to multiple expansion opportunities: an LGS sNDA already filed, a CDD Phase 3 starting soon, Europe reimbursement progress, and MT 1621 moving through development with encouraging efficacy and survival data.
The biggest near-term risk is execution timing: MT 1621’s NDA slipped to the second half of 2022 because Study 107 was delayed by the pandemic, and the company did not fully quantify how quickly LGS launch uptake might build. Management also acknowledged that Q3 patient adds were affected by Delta-related closures in July and August, and Europe still faces reimbursement complexity and potentially different labeling expectations from the EMA.
AI summary of the company's earnings call · Paraphrased · Not investment advice
of shares held by institutions
175 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Knott David M | 124.69K | 0 |
| Next Financial Group, Inc | 226 | 0 |
| Berman Capital Advisors, LLC | 175 | ▲ 175 |
Held by 2 ETFs
Biggest fund positions in ZGNX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 7, 22 | Smith Michael P | other | 8,016 |
| Mar 7, 22 | Smith Michael P | sell | 67,500 |
| Mar 7, 22 | Smith Michael P | sell | 39,000 |
| Mar 7, 22 | Smith Michael P | sell | 25,000 |
| Mar 7, 22 | Smith Michael P | sell | 35,499 |
| Mar 7, 22 | BREITMEYER JAMES B | sell | 6,250 |
| Mar 7, 22 | BREITMEYER JAMES B | sell | 20,000 |
| Mar 7, 22 | BREITMEYER JAMES B | other | 1,250 |
| Mar 7, 22 | BREITMEYER JAMES B | sell | 9,375 |
| Mar 7, 22 | BREITMEYER JAMES B | sell | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ZGNX coverage
Recent articles, reports, and earnings notes.
No research on ZGNX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZGNX report →Needle-Free Drug Injection Systems Business Analysis Report 2023-2030 Featuring AKRA Dermojet, Crossject, D`Antonio Consultants, PharmaJet, and Zogenix
globenewswire.com · Aug 1
Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022
globenewswire.com · Mar 4
Zogenix (ZGNX) Reports Q4 Loss, Tops Revenue Estimates
zacks.com · Feb 28
Why Zogenix Flew Higher Before Leveling Off This Week
fool.com · Jan 21
Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist
stockmarket.com · Jan 20
Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB
zacks.com · Jan 20
Zogenix (ZGNX) Stock Jumps 65.7%: Will It Continue to Soar?
zacks.com · Jan 20
ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today
investorplace.com · Jan 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.